Protara Therapeutics Inc
TARA
Get informed when a big investor buys or sells
+ FollowMarket Cap$156.67M
Close$
$1.08
73.4% downside
Current Fair Value
73.4% downsideOvervalued by 73.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $156.67 Million |
|---|---|
| Enterprise Value | $144.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 1.45 |
| Outstanding Shares | 42,836,129 |
Return
| Return on Equity | -34.94% |
|---|---|
| Return on Assets | -32.99% |
| Return on Invested Capital | -36.69% |
Valuation & Multiples
| P/E Ratio | -2.78 |
|---|---|
| PEG | -5.65 |
| Price to Sales | - |
| Price to Book Ratio | 1.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.16 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2429▲ 5.19% |
|---|---|
| Total Calls | 177,000▲ 148.60% |
| Total Puts | 43,000▲ 216.18% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.96%▲ 4.74% |
|---|---|
| Total Invested | $237.38M▲ 11.84% |
| Investors Holding | 118▲ 10.00% |
ESG Score
No data
About Protara Therapeutics Inc
CEO: Jesse Shefferman